Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California

Core Insights - Rakovina Therapeutics Inc. is actively engaging with potential partners and the investment community during the J.P. Morgan Healthcare Conference scheduled for January 12-16, 2026 [1][3] - The company is focusing on AI-powered drug discovery to advance innovative cancer therapies, particularly through its proprietary platforms Deep-Docking™ and Enki™ [4][5] Company Activities - Senior members of Rakovina's executive leadership will be in San Francisco for meetings with potential partners [1] - The company will also participate in Fierce JPM Week, which is part of the broader industry programming during the conference [2] Strategic Focus - The executive chairman highlighted the importance of the JPM week for high-quality in-person partnering discussions, especially given the interest in AI drug development [3] - Recent preclinical data presented at the Society for Neuro-Oncology meeting in November 2025 indicates that Rakovina's AI-designed ATR/mTOR dual inhibitors effectively penetrate the central nervous system and match or exceed the potency of leading clinical comparators [3] Pipeline Development - Rakovina has established a pipeline of distinctive DNA-damage response inhibitors, aiming to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [5]